Press & News

The next generation biopharmaceuticals

Press releases 2019

2019-11-15

Interim Report – January to September 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the third quarter of 2019.[read more]

Older press releases

2019-09-23

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi- and multi-specific drug projects, today announced its relocation to the Karolinska Institute Campus in Solna.[read more]

2019-09-20

Affibody and GE Healthcare to Collaborate on Development of Affibody® PET Imaging Tracers

Solna, Sweden, September 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced a strategic collaboration with GE Healthcare to develop and commercialize Affibody®-based PET imaging tracers, with initial focus...[read more]

2019-08-23

Interim Report – January to June 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter of 2019.[read more]

Affibodys latest Press releases

2022-06-03

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis Izokibep was well-tolerated, having a safety...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information